Browse News
Filter News
Found 329 articles
-
The Rise, Fall and Future of Novavax
3/21/2023
On Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024. BioSpace takes a deep dive into the vaccine maker's prospects. -
ixlayer Announces Formation of Advisory Board
11/1/2022
ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board.
-
Proteinase K Market Size to Hit Around USD 7.98 Billion by 2030
10/27/2022
According to Vision Research Reports, the global proteinase K market size was garnered at USD 3.7 billion in 2021 and is expected to hit around USD 7.98 billion by 2030, growing at a CAGR of 8.92% from 2022 to 2030.
-
Palantir Announces New Distinguished Members to Federal Advisory Board
10/19/2022
Palantir Technologies Inc. (NYSE: PLTR) announced four new additions to its Palantir Federal Advisory Board (PFAB).
-
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
-
SARS-CoV-2 typically enters the body via the nose or mouth. Because of this, many think a nasal spray vaccine would do a better job of preventing COVID-19 infection and cutting transmission than an injection.
-
Asahi Kasei Bioprocess to Showcase Award-winning MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing at ACHEMA 2022
7/27/2022
Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.
-
Dr. Soon-Shiong and ImmunityBio are on the final leg of what they hope will be the FDA approval of their drug N-803 (anktiva) for the treatment of bladder cancer.
-
908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS
6/2/2022
908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis.
-
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
5/25/2022
Neuropathix, Inc., a socially responsible pain management life sciences company, announced that it has reached an important milestone in the company's history.
-
David Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, may have found a new home at the NYU Grossman School of Medicine.
-
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
-
To cope, life sciences companies are undertaking a supply chain risk assessment, conducting make-or-buy assessments, investing in supply chain technology and identifying backup suppliers.
-
Moderna and Thermo Fisher Scientific Honored for COVID-19 Vaccine Efforts
4/14/2022
The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally.
-
Techmer PM Targeting the Medical Device Sector With Its Proven, Trusted Materials Design Expertise
4/4/2022
Techmer PM LLC, the Clinton-based compounder and materials design firm, has a robust portfolio of products and technologies to present to MD&M West attendees in Anaheim, Calif., April 12-14.
-
Albert Bourla, Pfizer’s CEO, took home a salary of $1.69 million in 2021. To Pfizer, he’s undoubtedly worth it, having led the company to its COVID-19 vaccine success.
-
In his new book, Warp Speed, Paul Mango said the realization that many healthcare workers didn’t want the vaccine, for instance, was shocking.
-
BioSpace talked with Paul Mango, one of the key leaders of Operation Warp Speed, about the experience.
-
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
3/2/2022
Pardes Biosciences, Inc. announced the appointment of Thomas G. Wiggans as Chief Executive Officer and Chair of the Board of Directors.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.